Regenerator Genetics, Inc “ the cutting edge of genetic and tissue engineering ”

1. Regenerator Genetics, Inc “the cutting edge of genetic and tissue engineering”

2. Executive Summary Regenerator Genetics, Inc is a genetic engineering company that intends to research, design, patent and market synthetic tissue samples related to surgical and medical niche markets.

3. Objectives • To create an unfounded market within field of genetic engineering with the help of leading-edge research & development. • To raise $100 million in “smart money” seed capital in the first half of 2008. • To achieve $100 million in revenue by the year 2012. • To obtain grants and funding from Gates & Wellcome Foundation and NIH totalling $50 million in 2008. • Acquistion by Biotech/Big Pharma, possibly by our potential partner Genentech, by Year 10 so as to capture capital investment.

4. Mission • “…research, design, patent and market synthetic tissue samples related to surgical and medical niche markets.” • “…save millions of lives and drastically improve the quality of life of burn victims all over the world.”

5. Management Team • The management team is the current management team from Genentech, a leading biotechnologycorporation • They were specifically chosen due to their related state of affairs and experience within the biotechnology firm where we truly believe that their current skill-sets and relatable industry experience will bode well for the setup and successful development of Regenerator Genetics, Inc.

6. Board of Directors • 1. J. Craig Venter – founder and originator in mapping of the human genome • 2. Elias A. Zerhouni, M.D. – NIH Director • 3. Brook Byers of KPCB Venture Capital • 4. James D. Watson - co-discoverers of the structure of DNA. • 5. Andrew C. von Eschenbach - Commissioner of the US FDA

7. Research Location and Facilities • 10 teams of compiled of Nobel Prize-winning scientists, research aides and postdoctoral students housed within a 200,000 sq ft. facility. • Located in the Bay Area in San Francisco and devoted solely to genetic and tissue engineering research where it will be surrounded by world class biomedical research universities as well as Genentech Inc.

8. Main Competitors: • Johnson & Johnson 181.64B • Genentech, Inc. 75.29B • Medarex, Inc. 1.32B • ImClone Systems 3.67B • Wyeth 56.08B

9. Wyeth • …involved with the discovery, development, manufacture, distribution, and sale of pharmaceuticals, & consumer healthcare. • Our product is so revolutionary that it offers something that this company simply can’t match.

10. Johnson and Johnson • It manufactures and sells various products in the health care field worldwide. • It operates in three market segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. • Not levered to biotech, would have difficulty competing inhouse.

11. Alliance Analysis • Genentech, Inc engages in the discovery, development, manufacture, and commercialization of bio-therapeutics in the US. • Similar Management Teams • Complementing products in biotech • Geographical Proximity

12. Marketing • Focus on Doctor and Hospital awareness and implementation • First market basic products piggyback new products as they come online • Let media handle customer awareness

13. Exit Strategy • Be acquired by large healthcare company at the end of the 10 year investment horizon • Possible sale to J&J, Wyeth, Genentech • Likely sale to Genentech if alliance is achieved in early stages